Omega Watch With Moon Phase
Understand the future landscape and how new classes will fit into the treatment algorithm
Competition intensifies in race to the top
How do KOLs think the pricing environment is shaping the uptake of new Prostate Cancer treatments?
the Unique Benefits of KOL Insight: Prostate cancer
drawn from North American and European professionals:
impact on current first line chemo treatments?
Prostate Cancer: Competition intensifies in race to the top examines the most prominent insights gained from the field key opinion leaders. The results of FirstWord research and analysis will help you to:
Evaluate the performance of companies with the most robust new product pipelines
Understand Omega Seamaster Moonphase
How will pricing affect Xofigo uptake?
Appreciate KOL calls for diagnostic biomarkers and understand the commercial threat and opportunity such products present
In what ways could biomarkers improve future Prostate Cancer disease management and what impact could this have on prescribing?
The Prostate Cancer KOL panel assembled for this Therapy Trends research is Omega Speedmaster Chronograph Automatic
Assess the impact of Xofigo arrival onto the market
Compare and contrast the clinical profile of Johnson Johnson Zytiga and Medivation/Astellas Xtandi and assess their competitive strengths and weaknesses
Prostate Cancer: Competition intensifies in race to the top answers key questions including:
Comprehend the current trends driving and shaping the global prostate cancer market
Competition in the major segments of prostate cancer are set to intensify, with new hormone drugs, radiation therapy, chemotherapy add ons and immunotherapies in the pipeline. The high level of unmet needs, premium pricing and patient population growth continue to make the market an attractive proposition for be developers. There remains a significant opportunity to generate substantial revenues in this highly segmented disease, in the therapeutic segment and also in advanced diagnostics.
Information contained on this page is provided by an independent third party content provider. WorldNow and this Station make no warranties or representations in connection therewith. The launches of Johnson Johnson Zytiga (abiraterone acetate) and Medivation/Astellas Xtandi (enzalutamide) has reinvigorated the post chemo treatment segment, while launch Omega Watch With Moon Phase of the first cancer vaccine Provenge (sipuleucel T; Dendreon) and Zytiga expanded approval had finally given new options in the pre chemo setting. With similar efficacy and tolerability profiles, Zytiga and Xtandi are currently vying for first line status in both the post and pre chemo disease settings as both drugs are set to generate blockbusting revenues despite clinical and health payer concerns about the high cost of treatment. The recent addition of Xofigo, the first licensed alpha emitter in prostate cancer, also represents a paradigm shift in treatment.
How might new therapies Omega Watches Speedmaster Automatic
What are the most promising late stage classes in development?
What are the current unmet needs and major challenges in prostate cancer treatment?
How will the new therapies be positioned against each other in each of the disease segments?
What clinical research trends do KOLs predict for future Prostate Cancer therapies?
Assess the commercial and clinical potential of the pipeline hormone drugs, radiation therapy, chemotherapy add ons and next generation immunotherapy
Omega Watch With Moon Phase
Omega Seamaster White
Copyright 2006–2007 Phoenix Gallery. All rights reserved. Site design by . . . || mccallum design